268 related articles for article (PubMed ID: 29769262)
21. Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas.
Sethi S; Epstein-Peterson Z; Kumar A; Ho C
Front Oncol; 2021; 11():739441. PubMed ID: 34888236
[TBL] [Abstract][Full Text] [Related]
22. Smoldering mantle cell lymphoma.
Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
[TBL] [Abstract][Full Text] [Related]
23. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
[TBL] [Abstract][Full Text] [Related]
24. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
[TBL] [Abstract][Full Text] [Related]
25. Identification of two subgroups of mantle cell leukemia with distinct clinical and biological features.
Vizcarra E; Martínez-Climent JA; Benet I; Marugan I; Terol MJ; Prosper F; Marco J; Sanchez D; Ferrandez A; Tormo M; Sarsotti E; Ferrer R; García M; Ortuño F; Montagud M; García-Conde J
Hematol J; 2001; 2(4):234-41. PubMed ID: 11920255
[TBL] [Abstract][Full Text] [Related]
26. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
[TBL] [Abstract][Full Text] [Related]
27. B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma.
van der Velden VH; Hoogeveen PG; de Ridder D; Schindler-van der Struijk M; van Zelm MC; Sanders M; Karsch D; Beverloo HB; Lam K; Orfao A; Lugtenburg PJ; Böttcher S; van Dongen JJ; Langerak AW; Kappers-Klunne M; van Lom K
Blood; 2014 Jul; 124(3):412-9. PubMed ID: 24891323
[TBL] [Abstract][Full Text] [Related]
28. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
29. SOX11, a key oncogenic factor in mantle cell lymphoma.
Beekman R; Amador V; Campo E
Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333
[TBL] [Abstract][Full Text] [Related]
30. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis.
Saksena A; Yin CC; Xu J; Li J; Zhou J; Wang SA; Lin P; Tang G; Wang L; Wang M; Miranda RN; Medeiros LJ; Li S
Hum Pathol; 2019 Jul; 89():71-80. PubMed ID: 31054894
[TBL] [Abstract][Full Text] [Related]
31. Molecular Pathogenesis of Mantle Cell Lymphoma.
Navarro A; Beà S; Jares P; Campo E
Hematol Oncol Clin North Am; 2020 Oct; 34(5):795-807. PubMed ID: 32861278
[TBL] [Abstract][Full Text] [Related]
32. An overlapping case of in situ mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma.
Matsuoka R; Sakamoto N; Sakata-Yanagimoto M; Chiba S; Noguchi M; Nakamura N
J Clin Exp Hematop; 2020 Dec; 60(4):169-173. PubMed ID: 33028761
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas.
Navarro A; Beà S; Fernández V; Prieto M; Salaverria I; Jares P; Hartmann E; Mozos A; López-Guillermo A; Villamor N; Colomer D; Puig X; Ott G; Solé F; Serrano S; Rosenwald A; Campo E; Hernández L
Cancer Res; 2009 Sep; 69(17):7071-8. PubMed ID: 19690137
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C; Zheng Y; Feng Y; Cao X; Xu C
Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
[TBL] [Abstract][Full Text] [Related]
36.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
37. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
[TBL] [Abstract][Full Text] [Related]
38. CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series.
Akhter A; Mahe E; Street L; Pournazari P; Perizzolo M; Shabani-Rad MT; Stewart DA; Mansoor A
J Clin Pathol; 2015 Oct; 68(10):844-8. PubMed ID: 26124315
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.
Iqbal J; Shen Y; Liu Y; Fu K; Jaffe ES; Liu C; Liu Z; Lachel CM; Deffenbacher K; Greiner TC; Vose JM; Bhagavathi S; Staudt LM; Rimsza L; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; McKeithan TW; Chan WC
Blood; 2012 May; 119(21):4939-48. PubMed ID: 22490335
[TBL] [Abstract][Full Text] [Related]
40. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
Condoluci A; Rossi D; Zucca E; Cavalli F
Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
